CD274 and non-small cell lung carcinoma: Immune checkpoint inhibitors (ICIs), particularly anti‐programmed death‐1 (PD‐1)/programmed death‐ligand 1 (PD‐L1) antibodies, have demonstrated efficacy in various solid tumours,9, 10, 11, 12 including NSCLC.